Master Protocol to Assess the Safety and Antitumour Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumours

Official Title

Master Protocol to Assess the Safety and Antitumour Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumours (IGNYTE-ESO)

Summary:

This trial will evaluate safety and efficacy of GSK3377794 in participants with solid tumours, initially in participants with synovial sarcoma. Adoptive T-cell therapy (ACT) is a therapeutic approach that uses T lymphocytes of participants with cancer, obtained by leukapheresis, with the aim of generating an anti-tumour T-cell immune response.

Trial Description

Primary Outcome:

  • Substudy 1: Overall response rate
  • Substudy 2: Overall response rate
Secondary Outcome:
  • Substudy 1 and 2: Time to response
  • Substudy 1 and 2: Duration of response
  • Substudy 1 and 2: Disease control rate
  • Substudy 1 and 2: Progression free survival
  • Substudy 1 and 2: Number of partiipants with adverse events (AEs) and serious adverse events (SAEs)
  • Substudy 1 and 2: Severity and duration of adverse events of special interest (AESIs)
  • Substudy 1 and 2: Number of participants with replication competent lentivirus (RCL)
  • Substudy 1 and 2: Number of participants with insertional oncogenesis
  • Substudy 1 and 2: Number of participants with clinically significant changes in hematology and clinical chemistry parameters
  • Substudy 1 and 2: Number of participants with clinically significant changes in urinalysis parameters
  • Substudy 1 and 2: T Cell Persistence of GSK3377794
  • Substudy 2: Number of participants with positive anti-drug antibodies (ADA) against GSK3377794
  • Substudy 2: Titers of ADA against GSK3377794
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumour-associated proteins that have been found in several tumour types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1/LAGE-1a have shown objective responses. GSK3377794 is the first generation of NY-ESO-1 specific T-cell receptor engineered T-cells. This is a master protocol consisting of a core protocol with multiple independent substudies, investigating GSK3377794 treatment in previously untreated (1L) Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO1+ advanced metastatic or unresectable synovial sarcoma (Substudy 1) and GSK3377794 as second line or higher (2L+) treatment HLA-A*02+ participants with NY-ESO-1+ advanced metastatic or unresectable synovial sarcoma who have progressed following treatment with anthracycline based chemotherapy (Substudy 2).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society